The Cooper Companies, Inc. (NASDAQ:COO) Shares Bought by Mariner LLC

Mariner LLC raised its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 10.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,142 shares of the medical device company's stock after purchasing an additional 3,220 shares during the period. Mariner LLC's holdings in Cooper Companies were worth $3,139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Byrne Asset Management LLC bought a new position in shares of Cooper Companies during the fourth quarter valued at approximately $33,000. OFI Invest Asset Management purchased a new stake in Cooper Companies in the fourth quarter worth $34,000. New Age Alpha Advisors LLC purchased a new stake in Cooper Companies in the fourth quarter worth $38,000. Covestor Ltd lifted its holdings in Cooper Companies by 35.5% during the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after buying an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new stake in Cooper Companies in the 4th quarter valued at about $49,000. 24.39% of the stock is owned by institutional investors.

Cooper Companies Stock Down 2.0 %

Shares of COO stock traded down $1.69 during mid-day trading on Friday, hitting $80.89. 1,150,372 shares of the stock traded hands, compared to its average volume of 1,423,576. The Cooper Companies, Inc. has a 52-week low of $69.81 and a 52-week high of $112.38. The stock has a market cap of $16.18 billion, a P/E ratio of 41.48, a P/E/G ratio of 2.25 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The stock's fifty day moving average is $82.13 and its two-hundred day moving average is $92.78.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to analysts' expectations of $981.25 million. Equities analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on COO. BNP Paribas raised shares of Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research report on Friday, March 7th. Robert W. Baird dropped their price target on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Piper Sandler restated an "overweight" rating and issued a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.